Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations

Tim H Ward1, Duncan C Gilbert2,3, George Higginbotham4, Chris M Morris5, Valerie Speirs6* and Nicola J Curtin7*

1Patient Advocate, National Cancer Research Institute (NCRI), London, UK
2Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, UK
3MRC Clinical Trials Unit at UCL, London, UK
4Southmead Hospital, Bristol, UK
5Newcastle Brain Tissue Resource, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
6Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK
7Newcastle Centre for Cancer, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

*Correspondence to: Valerie Speirs, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB24 2ZD, UK. E-mail: valerie.speirs@abdn.ac.uk; and Nicola J Curtin, Newcastle Centre for Cancer, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK. E-mail: nicola.curtin@newcastle.ac.uk

Abstract

Half of all cancer patients receive radiotherapy, which makes a substantial contribution to their long-term disease control/cure. There are significant inter-patient differences in response, both in terms of efficacy and toxicity (frequently delayed onset) which are difficult to predict. With the introduction of technological improvements (e.g. stereotactic body radiotherapy and proton therapy) and development of combination therapies (e.g. radiotherapy and immune checkpoint inhibition), predictive biomarkers are needed even more. Whilst genomic studies have contributed significantly to predictions of response to anticancer therapy, there is no doubt that more information can be gathered from patient tissue samples. Patients are willing to donate their tissues to biobanks and wish them to be used as widely as possible for high-quality research. We report here a survey of the current practices in the UK from several groups collecting material from patients in radiotherapy trials and have identified barriers to collecting and sharing data and samples. We believe the current situation represents a significant missed opportunity to improve the personalisation of radiotherapy. We propose a greater involvement of patients and/or their advocates, a standardisation of the patient information leaflet, consent form content and data set, with easy linkage to clinical data, which would facilitate widespread sample and data discovery and availability to other researchers. The greater sharing of data and samples, nationally and internationally, would facilitate robust multicentre studies and avoid duplication of effort.

Keywords: radiotherapy; biobanking

Introduction

In high-income countries, 50% of all cancer patients will receive radiotherapy [1] at some point in their treatment pathway, contributing to the curative treatment of 30–40% of patients [2]. Globally, the number of patients requiring radiotherapy increases year on year [3]. Radiotherapy (often with concurrent chemotherapy) is now the primary standard of care treatment for many cancers to facilitate organ preservation (e.g. head and neck, cervical, and anal cancers) with high rates of cure [4,5]. Radiotherapy remains an alternative to surgery across a number of situations (e.g. prostate and bladder cancers [6,7]) and as adjuvant therapy in, for example, breast cancer [8]. Technical refinements are facilitating hypo-fractionated treatments leading ultimately to stereotactic body radiotherapy [9] with patients receiving curative doses...
of radiotherapy in only a few treatments. Equally, novel immunotherapy combinations (e.g. non-small cell lung cancer [10]) continue to improve patient outcomes and broaden radiotherapy indications.

However, not all patients are cured and radiotherapy can be associated with serious and delayed sequelae, hence the potential of personalised treatment to improve both treatment efficacy and long-term quality of life. Progress is slow – for example, although the positive influence of tumour human papillomavirus (HPV) involvement on outcomes after (chemo)radiotherapy for head and neck cancer was first described a decade ago [11], trials of dose modulation based on this biomarker are yet to report [12]. Other studies utilise more general biomarkers of risk [13] as opposed to specific predictors of radiotherapy effect/toxicity.

Preclinical studies have identified multiple determinants of both radio-sensitivity and radio-resistance that have the potential to be used as predictive biomarkers for both response and undesirable sequelae. Searchable databases of genomic and transcriptomic information have contributed significantly to biomarker identification, notably The Cancer Genome Atlas [14]. The collection of blood samples for radiogenomics has accelerated recently [15]. However, to fully translate the accumulating knowledge into useable biomarkers for precision oncology, the biobanking of properly curated tumour and normal tissue samples, surplus to diagnostic/clinical need, is essential along with appropriate (anonymised) clinical data.

Tissue samples may be diagnostic biopsies, excess tissue from surgery, or collected as part of a clinical trial where participation mandates blood and/or tissue collection. Paired pre- and post-radiotherapy biopsies are extremely valuable for ‘proof of mechanism’ studies but particularly challenging to collect as the patient must consent to repeated invasive procedures. However, there are clinical indications for repeat biopsies post-treatment such as biopsy or removal of the primary tumour and secondary recurrence or, for example, sentinel lymph node biopsy in patients undergoing radiotherapy for breast cancer [16–18]. Whilst primary tumour samples can be difficult to obtain, blood sampling provides opportunities for ‘liquid biopsy’ of both circulating cell-free tumour DNA (ctDNA), circulating tumour cells (CTCs), and tumour extracellular vesicles pre- and post-radiotherapy [19]. These can be collected serially, avoiding the complications of invasive biopsies especially in hard-to-reach or high-risk tissues such as lung and brain, potentially yielding predictive biomarkers of radiotherapy response.

Patients want their material put to good use with the ultimate goal of improving the outcomes of patients in the future [20,21]. Quoting our patient representative, the key message here is that ‘Biobanks should not be Safety Deposit boxes accessed by the privileged few but more like open access accounts with stakeholders and others having easy access to deposit and withdraw’ [22].

Whilst clinical trials may include biobanking of patient material, these studies are usually small and collected for a specific purpose, limiting access. Where biobanking is part of a phase I trial of a novel drug, the availability of samples is less likely to be a major issue but, for a widely used treatment modality like radiotherapy, the desirability of sharing the material is increased. A UK survey of pathology departments identified inconsistency in tissue release for clinical trials, with lack of time and/or resources cited as the biggest barriers [23]. This, together with the lack of a standardised approach to consent, collection, handling, and storage, along with an often variable set of associated patient/ clinical data, presents challenges for samples to be shared/pooled in order to obtain meaningful data. The UK National Cancer Research Institute (NCRI) recognised this and, with the goal of improving biobanking in general, established the Confederation of Cancer Biobanks [24] in 2006, and incorporated it into the NCRI Cellular Molecular Pathology (CMPath) initiative in 2016; the objective is to share best practice, to improve the coordination between existing collections, and to raise awareness of existing collections. CMPath worked towards improving and standardising sample collection and reporting by devising a freely available Biobanking Sample Quality Improvement Tool [25] highlighted by the need for sample and data standardisation, especially for biomarker studies [26,27].

In radiotherapy biobanking, the GENEPI-ENTB2 project (GENEtic pathways for the Prediction of the effect of Irradiation-European normal and tumour tissue bank and database) sought to address shortfalls by establishing a database of patient treatment and outcome information, linked to a biobank of tissue samples [28]. This was achieved through the coordination of multiple small biobanks throughout the EU into a ‘virtual EU tissue bank’. The GENEPI-ENTB2 project documented 12,120 samples from 5,844 radiotherapy patients and 960 healthy volunteers [29]. The final report (2011) [30] highlighted challenges with the IT system and resources required for its management but provided a framework for future biobanking [29,31].

Learning from the experience of GENEPI-ENTB2 and CMPath, we sought to review the current UK landscape of radiotherapy-related biobanking and to propose a system of measures that might enable the effective collection, curation, and sharing of this
valuable resource given by patients altruistically to hopefully enable improvements in patient outcomes.

Public and patient involvement in biobanking

Patient material is a valuable resource, patients consent willingly, but their role in biobanking has historically been passive. Healthcare institutes are beginning to recognise patients as actively involved consumers or collaborators in research [32,33]. Nevertheless, patients still have no say over the scientific or clinical application of samples they have gifted. Patients have a right to know that their samples are valued, stored, and utilised appropriately, and that what will happen to them at the end of their shelf-life (including disposal) is clearly stated.

Some well-resourced UK biobanks, such as the charity-funded Breast Cancer Now Tissue Bank [34]; Blood Cancer UK CellBank [35]; Pancreatic Cancer Research Fund Tissue Bank [36]; and the part government, part charity-funded Wales Cancer Bank [37], involve patients in governance of the repository and tissue access committees and some include patients in the overall management of the biobank such that they know what happens to their samples and their contribution to research [33]. If we acknowledge that patients should be fully informed and engaged when consenting to donate, then this also applies when they are asked to comment/decide on the use of such samples [32]. Patient representatives can learn how to navigate the esoteric terminology and concepts through the Science for Advocates course developed by the Independent Cancer Patients’ Voice [38].

Large multicentre radiogenomics studies involving close co-operation across many countries have been successfully undertaken recently. REQUITE (Validating pREdictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve QUAIIty-of-life in cancer survivors) has its own associated biobank of centrally held samples, collected regularly from local centres [39]. The REQUITE project has patient representatives on both its management and publication committees. Patient involvement with such large projects is internationally acknowledged and implemented but seldom reported in publications. However, many smaller collections lack sufficient transparency to ensure that sample access can extend beyond the immediate clinical trial group to prevent monopolisation of the resources. The question of how applications for sample access are assessed and by whom is still an issue.

The UK radiotherapy biobanking landscape

To understand the current situation with respect to the collection of, and access to, biological samples in radiotherapy research in the UK, we devised a questionnaire that was sent to the 55 members of the NCRI Clinical and Translational Radiotherapy Research Working Groups (CTRad), requesting information regarding whether they collected tissue samples and, if so, the type of tissue samples, logistical infrastructure, current permissions regarding the sharing of tissue samples, and identifiable barriers to the storage and/or sharing of tissue samples (supplementary material, Section S1).

A total of 12 responses were obtained with 8 responders collecting tissues and 4 not collecting. The small sample size prohibited formal statistical analysis but provided a useful insight into the current landscape. Only two respondents collected tissue samples for general use with the remainder stating that consent was only obtained for sample use in the specified project, and samples could not be shared. However, most respondents would have been happy to share samples and data if access was appropriately peer reviewed and all would be happy to collect into a central biobank using a generic consent form and collection of a minimum data set if templates had been available. The majority of tissue samples and related data were stored in a study-specific database or a clinical trials research unit that were either part of a national, institutional, or individual biobank (Figure 1A,B). One barrier to sharing was discrepancies in the level of detail given regarding the future use or sharing of collected samples on the consent form. Detail ranged from ‘donating tissue for future research’ to specifying a permitted location, team, and funding for future research (Figure 1C). There was also variation in the demographic/clinical data collected (Figure 1D).

Numerous tumour sites were represented amongst samples collected, with the highest number of responses for samples of the prostate, pancreas, lung, and breast (Figure 2A) largely reflecting the clinical use of radiotherapy [40]. Samples were also collected at various time points in the treatment pathway (Figure 2B).

Regarding administrative support for biobanking, the most common was a data manager, followed by a biobank manager and quality assurance manager. The most common barrier to collecting, processing, and banking of tissue was a lack of facilities followed by a lack of biobanking support and lack of sample tracking software. These responses echo attitudes and practices uncovered by a related survey [23]. A second survey sent to the entire CTRad membership 2 years
Figure 1. Response to CTRad survey regarding collection of samples and data. (A) Where samples are collected, (B) how the data relating to the samples are stored, (C) restrictions on consent form (animal experimentation may not be permitted at all or only with restrictions, and (D) variability in the demographic and clinical data collected. Data are from 12 respondents out of 55 solicited. *Aetiology: relevant aetiological data (e.g. smoking history, HPV, body mass index, etc). MA, medical achiever; OS, overall survival; PFS, progression-free survival.

Figure 2. Responses from CTRad questionnaire regarding tissue collection and storage matrix. (A) Tumour types collected and (B) nature of samples taken. Data are from 12 respondents out of 55 solicited.
later elicited 57 responses of which 36 groups had the opportunity to collect patient material. Although only six answered all the questions, the data reflected the previous survey in that collections were generally as part of a clinical trial and those who did not collect cited lack of infrastructure or funding as the reason.

Recognising the low response rate to our survey, we contacted the chief investigators of all (68) studies held on the NIHR Clinical Research Network (CRN) Portfolio of clinical trials (March 2019) involving radiotherapy and/or observational/biomarker studies [41]. Responses were obtained from the investigators of 57/68 (84%) radiotherapy studies. Of these, 37 trials (65%) included translational components, with 35 collecting biological material. Twenty-five studies incorporated biobanking funding within the main study grant; the other 12 entailed separate, sequential applications (Figure 3A). The vast majority (35/37) were undertaking exploratory work – only 2 used collected biological material as stratification factors for the trial.

**Figure 3.** Status of tissue collection activity in recent UK radiotherapy studies. (A) Data from 57 (of 68 surveyed) UK radiotherapy studies. (B) Funding source for tissue collection for 35 studies that report biobanking biological material. (C) Integrating a sample collection (formalin-fixed, paraffin-embedded (FFPE) baseline and relapse samples) plus serial plasma in high-risk cases for cell-free DNA and CTCs within the UK Anal Cancer Platform trial PLATO (PLATO; Personalising Anal cancer radioTherapy dOse) maximises translational opportunities [42]. Patients were also co-enrolled into RAPPER, obtaining a whole blood sample for genome-wide association studies into the radiogenomics of toxicity [46]. Future radiomic and gut microbiome studies are in development.
These components were charity funded in 23 of 37 cases, many (14) by the Cancer Research UK. Six were funded by commercial (pharmaceutical industry) partners and three supported by the local academic institution. This distribution of funding sources concurs with responses to the initial questionnaire, suggesting most were funded by national or international charities (Figure 3B).

One example is the anal cancer platform PLATO (PersonaLising Anal cancer radioTherapy dOse; ISRCTN88455282) [42] funded by the Cancer Research UK and Stand Up to Cancer. Chemoradiotherapy represents standard of care in anal squamous cell carcinomas [5] where it is curative in this HPV-associated cancer [43]. Key translational questions include those around HPV transformation, radiotherapy sensitivity/response, and prediction of radiotherapy toxicity [44]. The integrated sample collection and biomarker analysis project (Figure 3C) funded in parallel includes a serial plasma collection, addressing these questions and more. Patients enrolled in PLATO are also encouraged to provide samples within the RAPPER study (Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy), investigating genomic predictors of toxicity [45,46]. With >10,000 patients, RAPPER is the largest radiogenomics resource in the world.

These data are in many ways encouraging. Nearly two-thirds of current UK clinical trials involving radiotherapy include collection/analysis of biological samples, supported by a variety of funders. Mostly, the translational work is exploratory; we are not yet in the era of biologically stratified radiotherapy studies. In addition, it remains unclear just how accessible this material, together with the important clinical demographic and treatment details, might be to future researchers. In registering a UK clinical trial, the Integrated Research Application System [47] specifically asks what will happen to tissue samples at the end of a study, providing the option to deposit samples within a biobank and using this option would ensure tissue samples can be made available. Internationally, one such exemplar is the French glioblastoma biobank [48].

**Future perspectives**

Material is clearly being collected from patients undergoing radiotherapy across a number of clinical trials but samples are neither as visible nor as accessible as they might be, use diverse consent forms, and collect different data points. With visibility and appropriate consent, they could be used by other researchers to improve radiotherapy (see the checklist in supplementary material, Section S2), for example, biomarkers predictive of (progression-free) survival following radiotherapy [49]. Advances in understanding the role played by DNA repair mechanisms in the cellular response to ionising radiation [50], and how the tumour micro-environment and immune response modulate outcomes [51], present a plethora of candidate biomarkers for translational research aiming to optimise radiotherapy treatments. The recent development of relatively non-invasive liquid biopsies (ctDNA and CTCs) means there is a greater potential to collect material for research into the molecular basis of radiosensitivity and toxicity, as exemplified recently by analyses of ctDNA collected from oesophageal cancer patients [52]. However, this can only be optimally exploited if the material is made available to diverse groups. The use of such tests has already impacted clinical decision-making in the non-radiotherapy setting such as the plasmaMATCH trial, which successfully used ctDNA to identify breast cancer patient subgroups who were sensitive to targeted therapies [53].

To address the lack of standardisation across consent forms, and associated discrepancies in permission for sharing tissue samples between studies, a standardised consent form may be desirable (supplementary material, Table S1). This was unanimously supported by respondents to the initial questionnaire, provided that sufficient support would be made available, and is an objective of CMPath. Such consent forms must consider the patients’ perspective, and recognise that cultural and spiritual backgrounds may have a bearing in this regard [54,55]. One important issue concerns the use of samples by pharmaceutical companies and for-profit researchers in discovery/validation programmes to avoid exploitation and promote accountability and recompense [56]. Involvement of patients as collaborators through Public Patient Involvement improves donor retention and recruitment. In addition, engagement with scientists improves the understanding of the importance and value of these gifted samples, and the expectations patients have on the output of the research.

Similarly, collection of a standardised set of clinical data (Table 1) would also facilitate sharing of sample collections and the acquisition of large numbers of samples pooled from several small studies to generate meaningful data. One issue here is the need for standardised terminology when describing available samples and the metadata associated with a sample. The Minimum Information about Biobank Data Sharing (MIABIS) approach provides a route to allow samples to be identified at the individual sample level and
identification of similar samples across biobanks and networks [57]. As an extension of this core data set, consented access to extended medical information of participants would allow future enrichment of any banked tissue samples, and this data use is largely accepted by the public in the UK. The Health Data Research UK (HDR-UK) provides a framework for acquiring consented access to medical information, providing secure data curation, and interoperable standards for data handling [58]. Similar activities such as ‘All of Us’ allow curated large-scale secure access to health data [59]. Integrating these data through ‘Research Data Hubs’ then means that specific large-scale data sets can be created and analysed in a secure environment with appropriate involvement of patient groups [60].

Virtual tissue banks that allow potential researchers to locate and request the use of specific samples exist, notably the UK Prostate Cancer Sample Collection Database [61]. Attached to each sample collection are data on the type of sample, location, and contact information for requesting use, for example, for the ProtecT (Prostate Testing for Cancer and Treatment) study [62]. Virtual tissue banks based on sample databases could act as models for a potential CTRad database. The UK Clinical Research Collaboration Tissue Directory (UKCRCTD) [63,64] serves as an online centralised register of relevant tissue samples in the UK, allowing researchers to locate specific samples, with researchers then contacting individual banks directly to access samples. Similarly, BBMRI-ERIC [65] provides a European and also international database that links national registers such as UKCRCTD to their national counterparts [66], with similar resources present in the US and Canada [67]. This provides greater access to potentially rare samples and cohorts, but also harmonisation of processes. A standardised ontology for biobanks has been derived through BBMRI-ERIC [68], and the MIABIS initiative [69] describes a hierarchical approach to allow banks, samples, and data to be described, providing interoperability across banks by incorporating accepted codes (e.g. the systemised nomenclature of medicine [SNOMED]) where appropriate. Despite these initiatives, many UK cancer biobanks still lack visibility, presenting challenges for researchers in identifying available samples and how these may be accessed [70] (see the checklist in supplementary material, Section S2).

Clear information on how biobanks indicate sample access and usage, and how applications for tissue are assessed, is needed. Standardised terms of access that provide a framework for both public and researchers to understand how samples and data can be accessed

Table 1. Recommended data set for biobanking.

| Identification (e.g. collection number with abbreviation for hospital and patient’s initials) | Consent form number, date of consent, name of person who took it |
| NHS number (to allow future linkage subject to appropriate data governance) | Consent coverage: general/specific project, consent to genetic (DNA) analysis |
| Consent details | Consent opt-outs, e.g. no commercial use |
| | Consent active/withdrawn |
| | Lab number (unique identifier for anonymisation) |
| | Diagnosis (including stage/grade, if [when] known) and date of diagnosis |
| Demographics | Age at diagnosis |
| | Sex |
| | Religious or moral status |
| | Tissue collection date |
| Sample details | Sample site (whole blood/lymphocytes/tumour/lymph node/adjacent normal tissue, etc) |
| | Sample description note (e.g. taken x h after treatment) |
| | Sample type (fresh/snap frozen/cryopreserved/FFPE or derivative sample, e.g. normal/tumour DNA) |
| | Storage location and number of aliquots if relevant |
| | Available for loan |
| | Histology sample number |
| Treatment details | Prior therapy and when given, if known |
| | Post sample therapy planned, if known |
| | Radiotherapy modality, dose, fractionation, and treatment volumes |
| Additional treatment | Chemotherapy/endocrine therapy/targeted therapy/immunotherapy details |
| Outcomes | Date of first recurrence (if/when known) |
| | Date of death (when known and cause of death) |
| | QOL/patient-reported outcomes (including late effects) |

FFPE, formalin-fixed paraffin-embedded tissue; QOL, quality of life.
have been provided by the UK NCRI and other large organisations [71,72]. Many tissue banks employ this process with access policies built around the process of applying for tissue. These focus on the eligibility to apply, the application process itself, the review of the application, who will be involved with the review of applications, the terms and conditions of access, and how the process is governed. Individual access policies for banks should be developed with the support of patient groups who should form an integral part of the access committee.

How do biobanks indicate access and usage for the informed patient and public at large? One possibility would be a dashboard system on their website displaying metrics such as number of samples in, number of access applications made, and the number of samples released to demonstrate that samples and data are being used [20,21]. Transparency of access is an issue but, with centralised resources such as those provided by the Medical Research Council’s Regulatory Support Centre [73], the use of templates describing access terms is becoming more common, with Research Tissue Banks providing these for applicants [72]. The application process for tissue can often be seen as opaque, and there is no unified standard for what constitutes an access committee. As a key principle, donor or lay input to evaluation of any application for tissue should be valued as equal to those of the scientists running the tissue bank. This would provide donors in particular, but also potential applicants from the translational radiotherapy research community, with the assurance that tissue banks are not static collections, but dynamic structures with a specific unified aim of distributing samples and improving patient care.

Recommendations for improvement

While good progress has been made in biobanking, there is still room for improvement in the radiotherapy field. Our data from the UK demonstrate a significant missed opportunity, given the number of patients receiving radiotherapy within clinical trials. Importantly, many biological samples and data sets potentially available (from clinical trials) will have broader relevance to the research community than the limited primary outcome measures might involve. Here, we champion some aspirational challenges for what could be done to achieve these aims for radiotherapy biobanking:

1. Due regard for the feelings, wishes, and rights of patients and participants related to: (i) transparency and rigor regarding access and research project approval; (ii) publications that acknowledge their anonymous contribution; (iii) generic consent forms and patient information leaflets that are easily understandable by patients (see supplementary material, Table S1 and Section S3); (iv) appropriate consent, curation, and storage to facilitate sharing of samples and data with the wider scientific community when the project is complete; and (v) the use of cost recovery from both academic and commercial users based on standardised tariffs for samples and data to support the long-term operation of the biobank.

2. Standard sample collection pathways. Quality guidelines and standards exist for biobanking [27] (see also supplementary material, Table S2), but do not seem to be adopted universally by those banks that are not required to follow these regulations. National and international guidelines have also been introduced and guidance provided by, for example, BBMRI-ERIC [64], providing frameworks that even small tissue banks can utilise. Additional professional standards for biobanking have been introduced such as ISO21899:2020 and ISBER Best Practice Guidance [74,75], although given the constraints placed on funding, these standards may be outside the budgets of many small biobanks. Stakeholders must overcome the challenges of local, regional, and national legislation, and come together to agree a universal standard for radiotherapy biobanking.

3. To facilitate sample discovery, standard checklists for applicants should be visible on biobank websites (see supplementary material, Section S2). These should detail sample types, who can access these, how (and by whom) applications are assessed, and if there are cost recovery mechanisms [70]. In this respect, use of centralised registries such as the UKCRC platform or the MIABIS ontology provides a way of biobanks being identified and utilised.

4. Sharing resources through virtual biobanks. The NCRI Prostate Cancer Initiative mentioned earlier, or the model implemented by SEARCHBreast, provides suitable templates [76]. In these examples, tissues remain at the originating laboratory but are listed on a secure searchable online database where researchers can find, share, or upload materials. With researchers placing increased demands on biobanks, in terms of the range and type of tissues and data being requested, one of the biggest challenges faced, particularly by smaller biobanks, is operational cost. Most biobanks are poorly resourced and often struggle to cover their costs. Funders may consider cost-sharing models whereby funding larger centralised facilities may provide economies of scale. Similarly, virtual biobanks offer a way of reducing, although not completely eliminating, such costs. In this
Radiotherapy biobanking: challenges and aspirations

respect, funders should consider making a condition of funding the improved visibility of biobanks.

5. Informatics allowing tissue to be linked to patient data represents a long-term goal to identify how biomarkers are related to patient therapies and outcomes. The HDR-UK [77] has provided a platform for health records and biomarker data to take place based on a series of specific tasks that allows for curated data analysis.

Summary

To conclude, we champion:

- Patient involvement from the outset, facilitated by generic consent forms which are easily understandable by lay persons
- Widespread sample discoverability and availability (no ‘ownership’; collegiality, considering patient wishes)
- Easy linkage to clinical data
- Sharing data (avoiding duplication of effort)
- Standard sample collection pathways

And appeal to funding bodies to prioritise these efforts.

Acknowledgements

This work was supported by the National Cancer Research Institute (NCRI) Clinical and Translational Radiotherapy Research Working Group (CTRad), which was established in 2009 by six of the NCRI’s funding partners. We gratefully acknowledge Carolyn Chan and Julie Stock (NCRI) for their assistance in collecting the responses to the questionnaire sent to CTRad membership.

Author contributions statement

NJC and VS conceived the project. GH, DCG and NJC analysed the data. GH and DCG collected the data. All authors contributed to the drafting and editing of the manuscript.

References

1. Delaney G, Jacob S, Featherstone C, et al. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005; 104: 1129–1137.

2. Bryant AK, Banegas MP, Martinez ME, et al. Trends in radiation therapy among cancer survivors in the United States, 2000-2030. Cancer Epidemiol Biomarkers Prev 2017; 26: 963–970.

3. Borras JM, Lievens Y, Barton M, et al. How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiother Oncol 2016; 119: 5–11.

4. Chow LQM. Head and neck cancer. N Engl J Med 2020; 382: 60–72.

5. James RD, Glynn-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol 2013; 14: 516–524.

6. Deamaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016; 2045: 1–14.

7. James ND, Hussain SA, Hall E, et al.; BC2001 Investigators. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012; 366: 1477–1488.

8. Murray Brunt A, Haviland JS, Wheatley DA, et al.; FAST-Forward Trial Management Group. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 2020; 395: 1613–1626.

9. Chalkidou A, Macmillan T, Grezda MT, et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol 2021; 22: 98–106.

10. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379: 2342–2350.

11. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24–35.

12. Anderson CM, Kimple RJ, Lin A, et al. De-escalation strategies in HPV-associated oropharynx cancer – are we putting the cart before the horse? Int J Radiat Oncol Biol Phys 2019; 104: 705–709.

13. Looke I, Drinkwater K. Implementation of Royal College of Radiologists Consensus Statements and National Institute for Health and Care Excellence Guidance: breast radiotherapy practice in the UK. Clin Oncol (R Coll Radiol) 2021; 33: 419–426.

14. National Cancer Institute GDC Data Portal. [Accessed 12 April 2021]. Available from: https://portal.gdc.cancer.gov/.

15. Shui L, Ren H, Yang X, et al. Trends in radiation therapy among cancer survivors in the United States, 2000-2030. Cancer Epidemiol Biomarkers Prev 2017; 26: 963–970.

16. Intra M, Viale G, Vila J, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2013; 14: 516–524.

17. Poodt IGM, Vugts G, Schipper RJ, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol 2013; 14: 516–524.

18. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378: 1707–1716.
19. López de Andrés J, Griñán-Lisón C, Jiménez G, et al. Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. J Hematol Oncol 2020; 13: 136.

20. Richter G, Krawczak M, Lieb W, et al. Broad consent for health care-embedded biobanking: understanding and reasons to donate in a large patient sample. Genet Med 2018; 20: 76–82.

21. Warner TD, Weil CJ, Andry C, et al. Broad consent for research on biospecimens: the views of actual donors at four U.S. medical centers. J Empir Res Hum Res Ethics 2018; 13: 115–124.

22. Gilbert DC, Speirs V. Biobanking in radiotherapy trials – a challenge to the clinical research community. Nat Rev Clin Oncol 2021; 18: 191–192.

23. Macklin PS, Hall A, Lee J, et al. Barriers to the release of human tissue for clinical trials research in the UK: a national survey of cellular pathology laboratories on behalf of the National Cancer Research Institute’s Cellular Molecular Pathology (CM-Path) initiative. J Clin Pathol 2019; 72: 52–57.

24. Confederation of Cancer Biobanks. [Accessed 12 April 2021]. Available from: https://cmpath.ncri.org.uk/ccb/

25. Speirs V, Foden H, Hair J, et al. GENEtic pathways for the Prediction of the effect of Irradiation-European normal and tumour tissue bank and data base. [Accessed 12 April 2021]. Available from: https://cordis.europa.eu/project/id/36437/reporting

26. De Ruyscher D, Severin D, Barnes E, et al. Report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPII-Radiother Oncol 2010; 97: 36–39.

27. Final Report Summary – GENEP II-ENTB 2 (GENEtic pathways for the Prediction of the effect of Irradiation-European normal an tumour tissue bank and data base). [Accessed 12 April 2021]. Available from: https://cordis.europa.eu/project/id/36437/reporting

28. De Ruyscher D, Severin D, Barnes E, et al. First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEP II. Radiother Oncol 2010; 97: 36–39.

29. Baumann M, Hölscher T, Begg AC. Towards genetic prediction of radiation responses: ESTRO’s GENEPI project. Radiother Oncol 2003; 69: 121–125.

30. Wilcox M, Grayson M, MacKenzie M, et al. The importance of quality patient advocacy to biobanks: a lay perspective from Independent Cancer Patients Voice (ICPV), based in the United Kingdom. Adv Exp Med Biol 2015; 864: 171–183.

31. Mitchel D, Geissler J, Parry-Jones A, et al. Biobanking from the patient perspective. Res Involv Engagem 2015; 1: 4.

32. Breast Cancer Now Tissue Bank. [Accessed 12 April 2021]. Available from: https://breastcancernow.org/breast-cancer-research/breast-cancer-now-tissue-bank

33. Blood Cancer UK Childhood Leukaemia Cell Bank. [Accessed 12 April 2021]. Available from: http://cellbank.org.uk/

34. Pancreatic Cancer Research Fund Tissue Bank. [Accessed 12 April 2021]. Available from: http://www.thepancreastissuebank.org/management.html

35. Wales Cancer Bank. [Accessed 12 April 2021]. Available from: https://www.walescancerbank.com/

36. Independent Cancer Patients’ Voice. [Accessed 12 April 2021]. Available from: http://www.independentcancerpatientsvoice.org.uk/voice-science-for-patient-advocates/

37. REQUITE: validating pRedictive models and biomarkers of radiotherapy toxicity to reduce side effects and improve QualITy of life in cancer survivors. [Accessed 12 April 2021]. Available from: https://www.requite.eu/

38. Sebag-Monteﬁore D, Adams R, Bell S, et al. The development of an umbrella trial (PLATO) to address radiotherapy dose questions in the loco-regional management of squamous cell carcinoma of the anus. Int J Radiat Oncol Biol Phys 2016; 96: E164–E165.

39. Baricicic I, He X, Chakrabarty B, et al. High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: different implications for vaccine prevention and prognosis. Eur J Cancer 2015; 51: 776–785.

40. Jones CM, Goh V, Sebag-Monteﬁore D, et al. Biomarkers in anal cancer: from biological understanding to stratified treatment. Br J Cancer 2017; 116: 156–162.

41. Barnett GC, West CM, Dunning AM, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009; 9: 134–142.

42. Burnet NG, Barnett GC, Summersgill HR, et al. RAPPER – a success story for collaborative translational radiotherapy research. Clin Oncol (R Coll Radiol) 2019; 31: 416–419.

43. IRAS: Integrated Research Application System. [Accessed 12 April 2021]. Available from: https://www.myresearchproject.org.uk/

44. Clavreul A, Soulard G, Lemée JM, et al. The French glioblastoma biobank (FGB): a national clinicobiological database [published correction appears in J Transl Med 2020; 18: 181]. J Transl Med 2019; 17: 133.

45. Ni J, Guo T, Li Y, et al. Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochecmical markers. Transl Lung Cancer Res 2019; 8: 967–978.

46. Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Sig Transduct Target Ther 2020; 5: 60.

47. Barker HE, Paget JT, Khan AA, et al. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 2015; 15: 409–425.

48. Azad TD, Chaadhuri AA, Fang P, et al. Circulating tumour DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology 2020; 158: 494–505.e6.

49. Turner NC, Kingston B, Kilburn LS, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer
Radiotherapy biobanking: challenges and aspirations

(PlasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol 2020; 21: 1296–1308.

54. Goodson ML, Vernon BG. A study of public opinion on the use of tissue samples from living subjects for clinical research. J Clin Pathol 2004; 57: 135–138.

55. Lewis C, Clotworthy M, Hilton S, et al. Consent for the use of human biological samples for biomedical research: a mixed methods study exploring the UK public’s preferences. BMJ Open 2013; 3: e003022.

56. Merz JF, Magnus D, Cho MK, et al. Protecting subjects’ interests in genetics research [published correction appears in Am J Hum Genet 2002; 7: 215]. Am J Hum Genet 2002; 70: 965–971.

57. Quinlan PR, Mistry G, Bullbeck H, et al.; Confederation of Cancer Biobanks (CCB) Working Group 3. A data standard for sourcing fit-for-purpose biological samples in an integrated virtual network of biobanks. Biopreserv Biobank 2014; 12: 184–191.

58. Sebire NJ, Cake C, Morris AD. HDR UK supporting mobilising computable biomedical knowledge in the UK. BMJ Health Care Inform 2020; 27: e100122.

59. All of Us Research Program Investigators, Denny JC, Rutter JL, et al. The "All of Us" Research Program. N Engl J Med 2019; 381: 668–676.

60. Gallier S, Price G, Pandya H, et al. Infrastructure and operating processes of PIONEER, the HDR-UK Data Hub in Acute Care and the workings of the Data Trust Committee: a protocol paper. BMJ Health Care Inform 2021; 28: e100294.

61. UK Prostate Cancer Sample Collection Database. [Accessed 12 April 2021]. Available from: http://prostatedatabase.org.uk

62. ProteCt Study. [Accessed 12 April 2021]. Available from: https://prostatedatabase.org.uk/infoSeries.php?id=101

63. Tissue Directory and Coordination Centre. [Accessed 12 April 2021]. Available from: https://biobankinguk.org/

64. Quinlan PR, Lawrence E, Pourabdollaet A, et al. The UK Clinical Research Collaboration (UKCRC) Tissue Directory and Coordination Centre: the UK’s centre for facilitating the usage of human samples for medical research. Open J Biosour 2017; 4: 6.

65. BBMRI-ERIC Biobanking and Biomolecular Resources Research Infrastructure-European Research Infrastructure Consortium. [Accessed 12 April 2021]. Available from: https://www.bbmini-eric.eu

66. Mayrhofer MT, Holub P, Wutte A, et al. BBMRI-ERIC: the novel gateways to biobanks. From humans to humans. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2016; 59: 379–384.

67. National Cancer Institute Specimen Resource Locator. [Accessed 6 August 2021]. Available from: https://www.specimens.cancer.gov/search/

68. Biobanking Resource Center. [Accessed 6 August 2021]. Available from: https://biobanking.org/locator

69. Norlin L, Fransson MN, Eriksson M, et al. A minimum data set for sharing biobank samples, information, and data: MIABIS. Biopreserv Biobank 2012; 10: 343–348.

70. Hall A, Speirs V & Hair J et al. Improving the discoverability of cancer biobanks. The Bulletin of the Royal College of Pathologists 2019; 186: 94–96.

71. BBMRI-ERIC Policy for Access to and Sharing of Biological Samples and Data. [Accessed 6 August 2021]. Available from: https://www.bbmini-eric.eu/wp-content/uploads/AoM_10_8_Access-Policy_FINAL_EU.pdf

72. NCRI Access Template. [Accessed 12 April 2021]. Available from: https://nsrc.ukri.org/documents/pdf/access-policy-development/

73. Centralised resources provided by the Medical Research Council’s Regulatory Support Centre. [Accessed 12 April 2021]. Available from: https://nsrc.ukri.org/research/facilities-and-resources-for-researchers/regulatory-support-centre/

74. ISO 21899:2020 Biotechnology — Biobanking — General requirements for the validation and verification of processing methods for biological material in biobanks. [Accessed 6 August 2021]. Available from: https://www.iso.org/standard/72118.html

75. International Society for Biological and Environmental Repositories. [Accessed 6 August 2021]. Available from: https://www.isber.org/

76. Blyth K, Carter P, Morrissey B, et al. SEARCHBreast: a new resource to locate and share surplus archival material from breast cancer animal models to help address the 3Rs. Breast Cancer Res Treat 2016; 156: 447–452.

77. Health Data Research UK. [Accessed 12 April 2021]. Available from: https://www.hdruk.ac.uk/

78. Mikkelsen RB, Gjerris M, Waldemar G, et al. Broad consent for biobanks is best – provided it is also deep. BMC Med Ethics 2019; 20: 71.

79. Betsou F, Lehmann S, Ashton G, et al. Standard preanalytical coding for biospecimens: defining the sample PREanalytical code. Cancer Epidemiol Biomarkers Prev 2010; 19: 1004–1011.

80. Moore HM, Kelly AB, Jewell SD, et al. Biospecimen reporting for improved study quality (BRIOSO). Cancer Cytopathol 2011; 119; 92–101.

81. Hartman V, Castillo-Pelayo T, Babinsky S, et al. Is your biobank up to standards? A review of the National Canadian Tissue Repository Network required operational practice standards and the controlled documents of a certified biobank. Biopreserv Biobank 2018; 16: 36–41.

82. Human Tissue Authority Codes of Practice. [Accessed 6 August 2021]. Available from: https://www.hta.gov.uk/hta-codes-practice-and-standards-0

83. IARC Biobank. [Accessed 6 August 2021]. Available from: https://iarc.fr/standards/index.php

84. Slokenberga S, Tzortzatou O, Reichel J (Eds). GDPR and Biobanking Individual Rights, Public Interest and Research Regulation Across Europe. Springer: Denmark, 2021.

References 78–84 are cited only in the supplementary material.

SUPPLEMENTARY MATERIAL ONLINE

Section S1. Questionnaires

Section S2. Suggested checklists to improve biobank visibility and transparency for researchers

Section S3. Key points for the patient information leaflet

Table S1. Generic consent form

Table S2. Existing guidelines